Modern approaches to treatment of uveitis in systemic diseases of connective tissue
Uveitis can develop in various systemic diseases of connective tissue. This article provides data on modern methods of treatment for such cases of uveitis. Uveitis in systemic diseases of the connective tissue develops due to violations of cellular and humoral immunity. Given the pathogenesis of the primary disorder, treatment of uveitis in systemic diseases of connective tissue involves use of cytotoxic drugs, TNFa inhibitors, cytokines, antibodies to lymphocyte surface antigens, and immunoglobulins. Due to the chronic course of the disorder and frequent relapses, it is advisable to use local and systemic glucocorticoid drugs with prolonged effect. The combined corticosteroid drug diprospan containing the two active ingredients of betamethasone provides a combination of immediate and prolonged effects, thereby improving patient's clinical condition and prolonging the period of remission.